SUMMARY -Rituximab is a chimeric monoclonal CD20 antibody used in the treatment of CD20 positive non-Hodgkin lymphomas and has revolutionized treatment approach to these hematologic malignancies in the last decade. Th e main aim of this review is to present data on the use of rituximab in the treatment of follicular lymphoma (FL). We will focus on rituximab maintenance strategies in the fi rst and second line treatment. Th is approach has improved the outcome in FL patients with better progression-free survival in all patients and better overall survival in relapsed setting. Regardless of good results, this strategy has generated controversies in medical community in the range from the lack of overall survival benefi t in fi rst line setting, adverse eff ects of possible overtreatment and toxicities to its unknown role in the era of novel agents. Th e existing data suggest that rituximab maintenance should be a rational therapeutic option for all patients with FL responding to fi rst line therapy and transplant-ineligible patients responding to reinduction.
Introduction
Follicular lymphoma (FL) is one of the most common subtypes of non-Hodgkin lymphoma (NHL). A recent survey in the United States that included 596,476 patients with newly diagnosed NHL over a period of 14 years demonstrated that FL was the second most common subtype of NHL, accounting for 17.1% of cases 1, 2 . In Croatia, the incidence of NHL is 5.57 per 100,000 of men or women, as reported by Novak et al. for the 2005-2009 period 3 . FL accounts for 20.2% of NHL cases in Croatia as demonstrated recently by the international NHL classifi cation project 4 . Th e histology of FL is characterized by germinal centers of B lymphocytes, predominantly centrocytes and centroblasts with follicular growth pattern 2, 5 . Th ey harbor universal translocation t(14;18)(q32;q21) involving the rearrangement of BCL2 and IgH in most cases. Morphologically, four diff erent grades are recognized, based on the number or centroblasts per high power fi eld with FL grade 4b being a distinct entity due to diff erent biological and clinical behavior 2, 6 . It is also characterized by expression of BCL2, BCL6, CD20, CD19 and monoclonal immunoglobulin light chain.
Th e course of the disease is marked by indolent course, frequent relapses, 'incurability', and tendency to transform into more aggressive NHL (diff use large B cell lymphoma). It is important to note that not all patients are treated initially due to the 'watch and wait' strategy. Th e most commonly used treatment criteria (GELF) are presented in Table 1 7 . Controversies remain regarding treatment rationale in cases of low tumor mass 8, 9 . Furthermore, newly diagnosed FL patients should be stratifi ed according to FLIPI-1 or FLIPI-2 criteria (Table 2 ) in order to predict the outcomes and overall survival (OS) 10, 11 . Th e main aim of this review is to analyze the existing data on the current treatment of FL with special emphasis on maintenance therapy.
Historical Overview of Advances in Follicular Lymphoma Th erapy
Prognosis in patients diagnosed with FL was poor. In a retrospective single-center analysis from the 1970s, the 5-year OS was 54%, deteriorating to 34% in patients older than 50 12 . Disease-free survival after 5-year follow up was only 18% of patients. However, these numbers improved as outlined by the recent EU-ROCARE 5 report 13 . A subanalysis for hematologic malignancies was performed for 1997-2007 including 32,110 FL cases 14 . Considerable improvement was recorded in 5-year OS of FL patients and in comparison to other lymphoid malignancies, rising from 58.9% in the 1997-1999 period to 74.3% in the 2006-2008 period. Th ere are several reasons for this improvement in outcomes, but for the purpose of this review we will state only two, i.e. the widespread introduction of rituximab, a chimeric antiCD20 antibody, and improvement in autologous stem cell transplantation (ASCT).
In the report of the European Society for Blood and Marrow Transplantation (EBMT) study, which included 693 patients followed-up for at least 15 years, the outcomes of ASCT for FL are presented 15 . Th e median progression-free survival (PFS) at 5, 10 and 15 years was 41%, 28% and 26%, respectively, with a plateau in the survival curve indicating satisfactory disease control in one-quarter of patients with relapsed or refractory FL. Th e median OS for ASCT at 5, 10 and 15 years was 64%, 52% and 47%, respectively. In a study of 121 patients undergoing ASCT at second remission or subsequent relapse, followed-up for at least 12 years, PFS was 55% at 5 year and 48% at 10 years 16 . Th ese results also show adequate tumor control, which can be obtained by ASCT. Th e only factor associated with longer OS was ASCT at 2 nd complete remission (CR). Th is treatment approach was also embraced offi cially by the leading international guidelines and subsequently by the Croatian Society of Hematology and Transfusion in the national lymphoma guidelines [17] [18] [19] . Another important improvement in the treatment of FL patients was the introduction of rituximab. Th e pivotal study included 166 patients with relapsed FL or other low grade NHL on infusion regimen with 375 mg/m 2 once weekly for 4 weeks 20 . Th e overall response rate (ORR) was 48% and PFS 13 months. Toxicities were mild and the effi cacy was comparable to the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen, then considered as the gold standard for indolent lymphomas. Th is study led to approval of rituximab for relapsed indolent NHL in 1997 21 . With its impressive activity and low toxicity profi le, the question arose if rituximab could be further combined with conventional chemotherapy to improve outcomes in these patients. Preliminary data on preclinical models sup- . However, it took years to translate these fi ndings into clinical reality. Th e fi rst pivotal randomized trial published in 2005 compared cyclophosphamide, vincristine and prednisone (CVP) with rituximab-CVP (R-CVP) 23 . It included 321 patients with stage III or IV FL. Primary objective was time to treatment failure (TTTF). TTTF was signifi cantly longer in R-CVP group as compared with CVP group (27 months vs. 7 months). ORR rates were 81% and 57%, respectively, indicating superior tumor control in rituximab group with prolonged duration of response (35 months vs. 14 months). Concerning toxicity profi le, the addition of rituximab resulted in infusion reactions that were manageable and higher rates of neutropenia but without any clinical repercussion. Th e authors conclude that R-CVP represents a novel, improved standard of care in FL, which was recognized by regulatory agencies 24 . Th e results of this study were updated with a longer follow up of 53 months showing the superiority of R-CVP with OS benefi t (83% vs. 77%) 25 . Subsequently, additional improvements of the fi rst line rituximab-containing regimen were explored. Rituximab was also included in the anthracyclinebased CHOP regimen in a trial including 428 high tumor burden FL patients 26 . Better ORRs, longer time to treatment failure (60% TTTF reduction) and duration of response, and better 2-year OS rates (95% vs. 90%) were achieved with R-CHOP as compared to CHOP. Th is study added to the on-going heated discussion whether to use anthracyclines in the frontline therapy for better tumor control in FL. A meta-analysis that included four clinical trials was performed to answer this review question 27 . Th erapy with R-CVP enabled higher CRs while R-CHOP was associated with better ORRs. However, the pitfall of this systematic review was not analyzing long term FL outcomes, and the authors conclude that the choice of the regimen should be decided individually based on the need to avoid anthracycline cardiotoxicity in older patients or in young patients where salvage therapy followed by ASCT is planned in the future. A recent Cochrane meta-analysis including 8 randomized control trials investigated the eff ect of adding anthracycline in treating FL on long term outcomes 28 . No OS benefi t was recorded while PFS was in favor of anthracycline usage. However, anthracycline was associated with higher toxicity, primary cytopenias and cardiotoxicity, which limit its application. Th e use of R-CHOP or R-CVP currently depends on the experts' judgment until the large observational trials such as RE-FLECT-1 provide answer to this question 29 . First line therapy including rituximab has achieved excellent tumor control and reduction, but the question remains if additional benefi t of rituximab may be exploited to reduce relapses and prolong PFS without the need for further cytotoxic treatment.
Th e Rationale for Rituximab as Maintenance Th erapy
After encouraging results of the pivotal study on rituximab, additional analysis was conducted based on the pharmacokinetics and response 20, 30 . Overall, rituximab serum concentrations increased and accumulated after each infusion with slow clearance during post treatment follow up. Additionally, the authors found that serum concentration of rituximab was signifi cantly higher in responders when compared to non-responders, especially during follow up. Additional parameters associated with elevated rituximab concentration were B-cell depletion, reduction of the largest tumor diameter, and the sum of diameter of six largest tumor lesions. Th e authors conclude that this may represent additional antitumor activity of rituximab and that higher concentrations may have a benefi cial clinical eff ect. Th ese fi ndings were further clinically confi rmed in a randomized control trial by Ghielmini et al. 31 . In 185 treatment naïve or relapsed FL patients, rituximab was administered once weekly for four weeks. After induction, they were randomized to receive additional four doses of rituximab every 8 weeks ('prolonged phase') or had no additional therapy. Primary outcome of the study was EFS which was signifi cantly longer in 'prolonged' group (23.2 months vs. 11.8 months). Overall, the risk of disease related event decreased by 60%. Th e prolonged treatment was not associated with any clinically relevant toxicity. In conclusion, prolonged rituximab exposure is associated with benefi cial eff ects in FL with more favorable outcomes. Th is trial provided evidence to further explore if rituximab could be used as maintenance therapy for reducing the relapse rates and the need for additional chemotherapy.
Maintenance with Rituximab in Relapsed Follicular Lymphoma
Th e fi rst randomized phase III trial explored rituximab maintenance in 176 patients with relapsed or refractory FL or mantle cell lymphoma 32 . Reinduction was induced with fl udarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab. Owing to the more favorable ORRs in R-FCM group, fi rst randomization was stopped and additionally recruited patients were allocated to R-FCM group. Second randomization of responding patients involved rituximab maintenance (2 courses of 4-times-weekly doses at 3 rd and 9 th month) and observation. Primary objective of the study was response duration, which was not reached in maintenance group vs. 17 months in observation group after median follow up of 26 months. When analyzing for the subtypes of NHLs, diff erence persisted in FL patients. Regarding toxicity, only one discontinuation occurred due to severe infusion reactions, but lymphocytopenia was most pronounced without infections.
A rituximab maintenance study in relapsed and refractory FL patients was carried out by EORTC group, involving 456 patients randomized at 1:1 ratio to receive either R-CHOP or CHOP as reinduction therapy 33 . Second randomization included rituximab maintenance administered once in 3 months for 2 years or observation. As expected, the addition of rituximab to CHOP regimen resulted in better ORRs and PFS. Promising disease control, defi ned as PFS of 51.5 months was achieved as compared to only 14.9 months in observation arm for the whole group. PFS remained signifi cant when adjusting for R-CHOP or CHOP regimens, for the fi rst time showing that maintenance strategy following the standard of care improved outcomes in these patients. Furthermore, PFS translated in OS benefi t with 3-year OS rate was 85.1% in maintenance group as compared with 77.1% in observation group. Additional safety risks arose in patients in the maintenance group being more prone to neutropenia (10.8%) and infections (9%). Th is toxicity was manageable and no death related to treatment was recorded. EORTC trial has demonstrated major improvements in care for relapsed or refractory FL patients, leading to approval of rituximab maintenance for this indication 20 . Long term follow up (median 6 years) of the trial was published, again demonstrating better PFS in maintenance group as compared to observation group (3.7 years vs. 1.7 years) 34 . However, the benefi t in OS was lost probably due to the bias produced by consequent retreatment regimens containing rituximab. Subsequent meta-analysis included 6 randomized controlled trials including 909 patients with relapsed or refractory FL 35 . Improved OS was seen in maintenance group with hazard-ratio of death estimated to 0.72. Th erefore, current evidence shows not only PFS, but also OS benefi t in this subgroup of patients (Table 3) . Accordingly, the Croatian national guidelines for lymphoma diagnostics and management have included rituximab maintenance in second CR or partial remission in transplant ineligible patients 19 .
Rituximab Maintenance as Part of First Line Th erapy of Follicular Lymphoma
Preliminary results of rituximab maintenance therapy after rituximab induction at four weekly doses showed improved PFS, as described previosly 31 . Another study explored this strategy in rituximab-naïve patients 36 . Th e study enrolled 387 patients suff ering from indolent NHL, most of them FL. Th e induction regimen was CVP. Patients were then randomized either to maintenance therapy (four doses of rituximab monthly at 6-month intervals, 4 courses) or observation arm. Th ree-year PFS was 68% in maintenance group versus 33% in observation group. PFS advantage did not signifi cantly translate into OS rates. More importantly, the study has reported conversion to better response to CVP during rituximab phase in 22% of patients compared with only 7% in observation group, indicating that not only rituximab maintenance improved outcomes in terms of PFS, but could additionally improve ORRs to prior induction regimen. No data on toxicity were provided in the study. Th ese studies used historical regimens (CVP, rituximab 4 doses weekly) and the need arose to explore maintenance strategy in contemporary setting. In one of the largest trials to date, PRIMA, which enrolled 1217 patients suff ering from untreated high burden FL, newer treatment regimens were used 37 . All patients were treated with one of the following chemotherapy regimens: R-CHOP, R-CVP or R-FCM. After the end of treatment, 1019 patients were randomized into rituximab maintenance group (rituximab therapy once in two months for two years) or observation group. Primary endpoint was PFS. Th e 3-year PFS rate was 74.9% in rituximab group as compared with 57.6% in observation group, with median follow up of 36 months. Furthermore, as shown by previous study, this strategy may contribute to conversion to optimal response, i.e. 72 patients with PR were converted to CR during the maintenance phase. Once again, PFS did not translate into OS benefi t. Results with a longer follow up (median 6 years) have been reported 38 . Th e 6-year PFS rate was 59.2% for maintenance group versus 42.7% in observation group. Time to next lymphoma treatment or chemotherapy was signifi cantly longer in the maintenance group. Th e maintenance strategy did not aff ect second line treatment of FL with CRs being similar between the groups. However, no signifi cant diff erence in OS has been reported. Based on the results of PRI-MA trial, rituximab was approved by regulatory agencies for another indication as fi rst line maintenance therapy in previously untreated FL responding to induction therapy 24 .
It should be stressed that one study did not fi nd benefi t of maintenance therapy in FL. Th is trial was conducted in elderly, untreated patients (N=234) using rituximab, fl udarabine, mitoxantrone and dexamethasone (R-FND). Patients were randomized in rituximab maintenance (one dose every four months, total of four doses) or observation arm. Primary endpoint of the study was 2-year PFS reaching 81% in rituximab group versus 69% in maintenance group. However, this diff erence was not statistically signifi cant (p=0.226) 39 . Th ere may have been several reasons, e.g., short follow up, limited rituximab exposure, small sample underpowered to detect diff erence and use of non-standard immunochemotherapy regimen in the fi rst line setting. An updated meta-analysis has consistently shown improvement in PFS across various studies (N=5), but again without translation in OS 35 . Data on rituximab in fi rst line maintenance therapy treatment of FL are summarized in Table 4 .
Controversies Surrounding Maintenance Th erapy in Advanced High Burden Follicular Lymphoma: to Maintain or not to Maintain?
So far, we have described relevant clinical trials of maintenance strategy in FL and several controversies have arisen. Th is will be discussed regarding routine clinical practice.
Th e role of autologous stem cell transplantation for relapsed follicular lymphoma in rituximab era
One of the few clinical trials examining ASCT and conventional therapy (N=89) showed OS and PFS benefi t, but was performed before the advent of rituximab 40 . Th e largest data set on ASCT comes from various retrospective series (e.g., EBMT), while data on ASCT during rituximab availability are scarce 15, 41 . In a retrospective analysis by the French GELA group, 254 patients with relapsed FL were included 42 . Patients treated with rituximab-based regimen had signifi cantly better outcomes (OS and EFS) than those treated with ASCT, but adding rituximab to salvage regimen followed by ASCT resulted in the most efficient disease control (OS and EFS not reached). According to the Croatian national guidelines, salvage chemotherapy containing rituximab followed by ASCT is recommended for young, fi t patients without signifi cant comorbidities 19 . Th e issue of possible omission of ASCT in FL must be resolved in the context of randomized clinical trial examining ASCT compared to rituximab maintenance approach. To our knowledge, no such trial has been performed. As stated previously, in transplant non-eligible patients, rituximab post-reinduction maintenance approach is a standard of care since benefi ts are recorded in both PFS and OS 17, 18, 35 .
Is progression-free survival a valid endpoint in follicular lymphoma?
One of the main criticisms of rituximab maintenance therapy in high tumor burden FL is the fact that improvement in PFS has not yet translated in OS benefi t by clinical trials and meta-analyses 31, [35] [36] [37] [38] [39] 43 . Several factors aff ecting OS in FL should be taken into account. First, FL is characterized by an indolent course leading to high OS rates and front-line rituximab contributed to 74.3% of 5-year OS rate 1, 14 . A follow up longer than 5 years would provide information if PFS will translate in OS. Second, for relapsed patients the established second line rituximab regimens and ASCT may result in additional OS interpretation bias due to long term remissions, which directly infl uences the OS curve. In a recent review by Korn and Crowley, PFS was highlighted as a powerful endpoint in clinical trials to be included in future studies 44 . In the time of accelerated approvals of cancer drugs on the basis of surrogate endpoints such as response rates with sufficient duration (i.e. pathologic complete response to neoadjuvant therapy in breast cancer) or molecular remissions (e.g., tyrosine kinase inhibitors for chronic myelogenous leukemia), evidence for clear PFS benefi t by rituximab maintenance in FL might be considered suffi cient ground for inclusion in routine protocols 45 .
To retreat or to maintain?
Rituximab has been established as maintenance therapy, but its possible role in retreatment was also assessed. Th e fi rst phase II randomized controlled trial included 114 rituximab naïve and previously relapsed patients with indolent NHLs 46 . Subjects fi rst received 4 weekly rituximab infusions followed by maintenance (four courses of 4 doses of rituximab every 6 months) or reinduction with rituximab after disease progression. Primary objective was duration of rituximab benefi t, which was 31.3 months in maintenance group versus 27.4 months in observation group. However, although the diff erence in primary outcome was not statistically signifi cant, PFS was signifi cantly longer in the maintenance group (31.7 vs. 7.4 months) with a higher rate of CRs and continuous remissions. When analyzing the results, we must take in account that this trial was designed in the era when rituximab was only approved for relapsed FL. Further bias when interpreting the results may be due to short follow up and unbalanced numbers across the groups 
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***** 234 R-FND PFS: 81% vs. 69% ****** Not reported for groups *median follow up 35 months; **median follow up 3.7 years, 3-year survival rates; ****median follow up 3 years, 3-year survival rates; *****median follow up 6 years, 6-year survival rates; ******median follow up 2 years, 3-year survival rates; ******nonsignifi cant; R = rituximab; CVP = cyclophosphamide, vincristine, prednisone; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone; FCM = fl udarabine, mitoxantrone, cyclophosphamide; FND = fl udarabine, mitoxantrone, dexamethasone; EFS = event-free survival; PFS = progression-free survival due to early progressions prior to starting maintenance therapy. Th e groundbreaking trial was the RESORT trial including 289 treatment naïve low burden FL patients 47 . After 4 weeks of rituximab induction, the subjects were randomized to either receive single rituximab infusion every 13 weeks (maintenance group) or reinduction in case of progression (retreatment group). Th e study had two primary objectives, i.e. TTTF and time to fi rst cytotoxic therapy. TTTF did not statistically diff er between the groups being 3.9 years in retreatment group versus 4.3 years in maintenance group. Time to fi rst cytotoxic therapy was signifi cantly longer in maintenance group as compared to retreatment group. Th e authors concluded that the retreat scheme was as effi cacious as maintenance strategy, therefore reducing overtreatment in this group. Th e results of this study were greeted with great enthusiasm by maintenance opponents as the 'fi nal nail in maintenance coffi n' 48, 49, 53 . Still, great care should be exercised regarding extrapolation of these results to treatment of advanced FL. Considering the relatively short EFS of 11.8 months in fi rst line rituximab induction therapy without extended use, retreatment strategy may not be as eff ective in high tumor burden FL, but this presumption was not analyzed. Although the retreatment option with rituximab may be attractive due to the acceptable toxicity profi le and probable cost-eff ective benefi t, in the absence of data for advanced FL, standard maintenance therapy should represent good clinical practice.
Toxicity of rituximab maintenance
Concerning the safety profi le of rituximab maintenance, the largest set of data comes from the PRIMA trial 37 . Th e frequency of adverse events equal and greater than 3 occurred in 24% of patients in maintenance group as compared to 17% events in observation group. Th e most common events were new malignancy (4%), neutropenia (4%) and infections (4%). Discontinuation rate due to adverse events was 4% in maintenance group. Continuous rituximab exposure can cause low plasma immunoglobulins, but no signifi cant decrease in immunoglubulins A, M and G was found in either group. Also, the incidence of transformation to aggressive diff use large B cell lymphoma did not diff er between the groups and no other safety risks were observed 38 . Safety of rituximab maintenance treatment was investigated in MAXIMA, a phase IIIb trial, including 545 patients with previously untreated or relapsed FL 50 . Hematologic adverse events equal and greater than 3 occurred in 4.4% of subjects with the most prominent event being neutropenia (2.4%), but only 4 cases of febrile neutropenia were recorded. Concerning infections, 4.3% of events equal or greater than 3 were recorded, with pneumonia as the most frequent one. Infections of grade 1 or 2 were more common, including nasopharyngitis (7.1%), bronchitis (4.7%) and sinusitis (4.3%). Grade 3 or 4 hypoimmunoglobulinemia developed in 4 patients, and in 32 patients hypoimmunoglobulinemia was of prolonged duration, but this event was self-limiting and did not require intervention in most cases.
In a systematic review of rituximab maintenance therapy that included 11 clinical trials and 1009 patients suff ering from FL or MCL, suppression of bone marrow and infections were most common toxicities, with 24% of patients experiencing grade 3 or 4 toxicity 51 . Signifi cantly less toxicity was found in the regimen of 4 weekly rituximab infusions every 6 months compared to PRIMA schedule (once in two months for 2 years), i.e. 12% and 35%, respectively. Th e systematic review also included MCL patients, which probably aff ected the results, as MCL patients are treated with more aggressive therapy in fi rst line treatment (high doses of cytarabine with cumulative toxicity). Rituximab maintenance therapy is associated with few side eff ects, which are tolerable and mostly do not cause discontinuation. While PRIMA schedule should remain the standard of care, in specifi c patient populations (elderly, unfi t, and those prone to infectious complications) alternative approach with rituximab (four weekly doses every 6 months for four cycles) may be a sound option.
Rituximab maintenance therapy and quality of life
Th e World Health Organization defi nes the quality of life (QoL) as the "individuals' perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns" 53 . QoL as an important medical issue has substantial impact on designing of clinical trials, mostly as self-reported secondary endpoint. Two diff erent QoL questionnaires were applied in PRIMA trial and no diff erence was found between maintenance and observation group 37 . Th is has led to criticism that QoL is not improved in these patients, thus failing in secondary endpoint 43 . Th is is apparently confl icting, but the treatment did not further deteriorate QoL. Also, patients were censored at the time of progression, so prospective data on the possible deterioration in QoL during relapse and the true impact of maintenance strategy on QoL will remain unknown. It is important to note that relapsed FL patients experience a rapid decline in QoL, as demonstrated in a series of 222 patients during diff erent disease states, but in relapsed setting 53 . Th e improvement in QoL as a valid surrogate outcome of treatment was recently raised by a prospective clinical trial including 379 asymptomatic, low tumor burden FL patients 9 . Th e main question of the trial was comparison of outcomes between the 'watch and wait' strategy versus rituximab treatment. By randomizing patients into three groups ('watch and wait', rituximab induction, and rituximab maintenance), the authors showed the expected improvement in time to next therapy in rituximab groups. Interestingly, the second main endpoint was improvement in QoL. Th e active approach, i.e. rituximab maintenance, signifi cantly improved QoL in these patients, indicating that active approach towards illness improves many lifestyle aspects, including coping mechanisms and emotional status. QoL as primary endpoint has its drawbacks due to the existence of various, more cost-eff ective interventions in this group such as psychotherapy 54 . In conclusion, it is hard to extrapolate the fi ndings of these studies, whether maintenance therapy improves QoL of FL patients indeed, but it is important to note that this strategy does not have negative impact, thus suggesting another argument for the validity of this approach.
Th e cost-eff ectiveness of rituximab maintenance
Th e cost of rituximab maintenance strategy is an important issue 43 . In a recent retrospective health economics US study that included 1002 patients with FL from MEDICARE database, the cumulative one-year cost for patients that progressed was 30,890 USD (N=268) versus only 8704 USD for those in observation group (N=734) 55 . Th e outpatients, inpatients, chemotherapy and acute care visits were more frequent in progression group associated with higher cost of care and its impact on healthcare system. Th is study indirectly provides the rationale that the prolongation of PFS in FL patients is associated with lower healthcare burden and costs, and provides evidence that maintenance therapy can indeed be cost-eff ective. One of earlier cost-eff ectiveness studies of rituximab maintenance comes from the Swedish group 56 . Th ey based their fi nancial model on the phase III trial in relapsed setting conducted by EORTC group 33 . Incremental cost per quality-adjusted life-years (QALY) was estimated to 12,600 € for rituximab group, while the cost per life-years-gained (LYG) was 11,200 €. In all of the simulations, rituximab maintenance was associated with incremental costs which were less than 25,400 €. With regard to willingness-to-pay value in Sweden of up to 54,000 € per intervention, rituximab maintenance in relapsed setting was cost-eff ective. Recently, a Dutch population-based study used registry data comprising 3581 patients with relapsed FL undergoing maintenance therapy 57 . Th e incremental cost-eff ectiveness ratio (ICER) was 11,254 € per QALY and 10,591 € per LYG. ICERs slightly diff ered in two studies (EORTC trial and matched-real world scenarios), but in conclusion rituximab maintenance in relapsed patients was found to be cost-eff ective and in line with Dutch healthcare policy makers. Similar results were obtained by a French economic analysis based on EORTC trial estimating ICER of 7612 € per LYG and 8729 € per QALY 33, 58 . Th ese data demonstrate that rituximab maintenance is cost-eff ective in relapsed FL setting and its ICER is well below willingness-to-pay value for oncologic drug.
Th e earliest data on rituximab maintenance costeff ectiveness in fi rst line setting come from US group based on the results of PRIMA trial 37, 59 . Total cost of maintenance therapy was estimated to be 38,545 USD with ICERs being 31,394 and 34,842 USD for LYG and QALY, respectively. Th e majority of US studies use ICER per QALY threshold as 50,000 USD, this approach seems to be cost-eff ective from US point of view 60 . In Europe, only one health economics study from the UK National Institute for Health and Care Excellence examined rituximab maintenance 61 . Most of ICERs per QALY were under 30,000 GBP, as reported by the manufacturer, while Evidence Review Group estimated ICERs per QALY to range between 24,600 and 35,000 GBP based on the scenario. Th e review group has concluded that rituximab maintenance is cost eff ective for the National Health System resources, which evaluate ICER per QALY as 30,000 GBP. Data were from primary PRIMA study with a short follow up, which possibly infl uenced the results. Future studies including real-world data are needed to address this issue.
Rituximab maintenance at the dawn of new drugs for indolent non-Hodgkin lymphoma: still necessary?
Th e past several years have certainly been exciting for indolent NHLs, particularly FL with the introduction of new drugs possibly changing treatment options. Th e fi rst drug of interest is certainly bendamustine (B), an 'old', but new drug in the fi eld. Bendamustine acts as a potent alkylating agent, indeed more potent than cyclophosphamide 62 , which also is not cross-resistant with other members from the group. Th e activity of bendamustine was demonstrated in early clinical trials in refractory or relapsed indolent NHLs resulting in high ORRs and durable remissions as a single agent or in combination therapy resulting in FDA approval for rituximab-resistant indolent NHLs 63 . However, the true value of bendamustine was recognized in fi rst line therapy of iNHLs. First randomized clinical trial compared bendamustine in combination with rituximab (R-B) to standard R-CHOP therapy in indolent and mantle cell lymphomas 64 . Th is combination resulted in improved PFS when compared to standard arm across all NHLs histology. Also, its toxicity was more tolerable with fewer hematologic and other adverse events (mostly infections). Th e results of this trial produced the hype that the era of R-CHOP had ended 65 . However, despite the non-inferiority design, BRIGHT study compared R-B to R-CHOP or R-CVP and did not demonstrate superiority in terms of ORRs, while PFS was not reported 70 . Adverse events included more hypersensitivity reactions, vomiting and nausea, and infection rate was not reduced. Th ese results sparked doubt on the role of bendamustine in fi rst line treatment and ongoing controversy whether B-R regimen should replace current standard regimens in FL and has not been granted universal approval for this indication. Nevertheless, ever more patients are being treated with B-R regimen questioning appropriateness of which has led to the question whether subsequent rituximab maintenance still plays a role in this setting. Rituximab maintenance following B-R induction is being evaluated in the ongoing MAINTAIN study 67 . Preliminary results have shown feasibility of the approach, but we will have to wait if diff erence in PFS will be achieved between maintenance arms and observation arm.
Th e greatest challenge to rituximab maintenance poses the relatively new introduction of B-cell receptor (BCR) pathway inhibitors into the fi eld of NHLs 68 . Th ese agents have rapidly changed therapy approach as tyrosine kinase inhibitors. In indolent NHLs, the most important member of the class is currently idelalisib, a phophatidylinositol-3 kinase δ inhibitor. Based on the preliminary data on its activity in indolent NHLs, a randomized, clinical trial was performed on 125 heavily pretreated patients with indolent NHLs 69 . Idelalisib has shown satisfactory activity with ORR of 57% and median duration of response of 12.5 months, which was granted by FDA approval for refractory and relapsed indolent NHLs 70 . Although this agent alone cannot produce durable CRs, its low toxicity in relapsed setting and new mechanism of action make idelalisib a preferable target for various combinations. Recently, a great setback has occurred with idelalisib 71 . Th e interim safety analysis of trials exploring idelalisib in combinations with cytotoxic drugs has shown inferior OS due to toxicity profi le (Pneumocystis jirovecii infections, cytomegalovirus reactivation, high rates of transaminitis and pneumonitis), which led to suspension of RCTs in fi rst line setting. Other BCR pathway inhibitors for indolent NHLs, such as venetoclax, are explored in phase I/II trials and proper introduction of these agents in real time clinical practice will not occur soon.
Conclusion
Th e existing data indicate that rituximab maintenance in advanced high tumor FL is effi cient for:
1. prolonged PFS 2. prolonged OS in relapsed FL 3. optimization of response 4. low toxicity profi le 5. adequate cost-benefi t profi le 6. no negative interference with QoL Recommended treatment algorithms are presented in Figures 1 and 2 . Rituximab maintenance may be used in fi rst and second line treatment of advanced high tumor burden FL according to the national guidelines for lymphoma diagnosis and treatment 19 . Despite current controversies surrounding this strategy, current data suggest that rituximab maintenance may and need to be employed in modern treatment of FL. 
